Impact of Psychosocial Risk Factors on Outcomes of Atrial Fibrillation Patients undergoing Left Atrial Appendage Occlusion Device Implantation.


Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 03 2023
accepted: 30 03 2023
medline: 5 12 2023
pubmed: 5 4 2023
entrez: 4 4 2023
Statut: ppublish

Résumé

The impact of psychosocial risk factors (PSRFs) on outcomes in patients undergoing percutaneous left atrial appendage occlusion (LAAO) device implantation is unclear. We aimed to analyze the association of psychosocial risk factors with outcomes in patients undergoing LAAO. Data were extracted from the Nationwide readmissions database for the calendar years 2016-2019. LAAO device implantations were identified using ICD-10-CM code 02L73DK. The outcomes of interest included procedural complications, inpatient mortality, resource utilization, and 30-day readmissions. Patients were divided into two cohorts based on the absence or presence of PSRFs. Our cohort included a total of 54,900 patients, of which, 19,984 (36.4%) had ≥ 1 PSRF as compared to 34,916 (63.6%) with no PSRFs. The prevalence of major complications (3.3% vs 2.8%, p=0.03) was significantly higher in patients with ≥ 1 PSRF as compared to no PSRFs. Furthermore, patients with ≥ 1 PSRF had a significantly higher 30-day readmission rate (6.9% vs 6.2%, p=0.02). In the multivariable model, the presence of ≥ 1 PSRF was associated with significantly higher odds of overall complications [adjusted odds ratio (aOR):1.11; 95% confidence interval (CI): 1.01-1.21; p=0.02]. Additionally, the presence of ≥ 1 PSRF was associated with higher odds of prolonged hospital stay for more than one day (aOR: 1.30; 95% CI: 1.21-1.40; p<0.01). The high prevalence of PSRFs may be associated with poorer outcomes in patients with AF patients undergoing LAAO device implantations. These data merit further study to help in the selection process of patients for LAAO for improved outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The impact of psychosocial risk factors (PSRFs) on outcomes in patients undergoing percutaneous left atrial appendage occlusion (LAAO) device implantation is unclear. We aimed to analyze the association of psychosocial risk factors with outcomes in patients undergoing LAAO.
METHODS METHODS
Data were extracted from the Nationwide readmissions database for the calendar years 2016-2019. LAAO device implantations were identified using ICD-10-CM code 02L73DK. The outcomes of interest included procedural complications, inpatient mortality, resource utilization, and 30-day readmissions. Patients were divided into two cohorts based on the absence or presence of PSRFs.
RESULTS RESULTS
Our cohort included a total of 54,900 patients, of which, 19,984 (36.4%) had ≥ 1 PSRF as compared to 34,916 (63.6%) with no PSRFs. The prevalence of major complications (3.3% vs 2.8%, p=0.03) was significantly higher in patients with ≥ 1 PSRF as compared to no PSRFs. Furthermore, patients with ≥ 1 PSRF had a significantly higher 30-day readmission rate (6.9% vs 6.2%, p=0.02). In the multivariable model, the presence of ≥ 1 PSRF was associated with significantly higher odds of overall complications [adjusted odds ratio (aOR):1.11; 95% confidence interval (CI): 1.01-1.21; p=0.02]. Additionally, the presence of ≥ 1 PSRF was associated with higher odds of prolonged hospital stay for more than one day (aOR: 1.30; 95% CI: 1.21-1.40; p<0.01).
CONCLUSION CONCLUSIONS
The high prevalence of PSRFs may be associated with poorer outcomes in patients with AF patients undergoing LAAO device implantations. These data merit further study to help in the selection process of patients for LAAO for improved outcomes.

Identifiants

pubmed: 37016070
doi: 10.1007/s10840-023-01546-4
pii: 10.1007/s10840-023-01546-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2031-2040

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399–410. https://doi.org/10.1161/01.cir.0000442015.53336.12 .
doi: 10.1161/01.cir.0000442015.53336.12 pubmed: 24446411
Saposnik G, Gladstone D, Raptis R, Zhou L, Hart RG. Investigators of the Registry of the Canadian Stroke Network (RCSN) and the Stroke Outcomes Research Canada (SORCan) Working Group. Atrial fibrillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes. Stroke. 2013;44(1):99–104. https://doi.org/10.1161/STROKEAHA.112.676551 .
doi: 10.1161/STROKEAHA.112.676551 pubmed: 23168456
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0 .
doi: 10.1016/S0140-6736(13)62343-0 pubmed: 24315724
Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–84. https://doi.org/10.1016/j.jacc.2017.03.540 .
doi: 10.1016/j.jacc.2017.03.540 pubmed: 28521884
Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med. 2005;20(12):1114–9. https://doi.org/10.1111/j.1525-1497.2005.0242.x .
doi: 10.1111/j.1525-1497.2005.0242.x pubmed: 16423100 pmcid: 1490282
Ravvaz K, Weissert JA, Jahangir A, Ruff CT. Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. PloS One. 2021;16(3):e0248134. https://doi.org/10.1371/journal.pone.0248134 .
doi: 10.1371/journal.pone.0248134 pubmed: 33735259 pmcid: 7971564
Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial [published correction appears in JAMA. 2015 Mar 10;313(10):1061]. JAMA. 2014;312(19):1988–98. https://doi.org/10.1001/jama.2014.15192 .
doi: 10.1001/jama.2014.15192 pubmed: 25399274
"Healthcare Cost and Utilization Project. Overview of the Nationwide Readmissions Database (NRD)". https://www.hcup-us.ahrq.gov/nrdoverview.jsp . Accessed January 23, 2023.
Khan MZ, Munir MB, Darden D, Pasupula DK, Balla S, Han FT, et al. Racial disparities in in-hospital adverse events among patients with atrial fibrillation implanted with a Watchman left atrial appendage occlusion device: a US national perspective. Circ Arrhythm Electrophysiol. 2021;14(5):e009691. https://doi.org/10.1161/CIRCEP.120.009691 .
doi: 10.1161/CIRCEP.120.009691 pubmed: 33909473 pmcid: 8521630
Munir MB, Khan MZ, Darden D, Pasupula DK, Balla S, Han FT, et al. Pericardial effusion requiring intervention in patients undergoing percutaneous left atrial appendage occlusion: Prevalence, predictors, and associated in-hospital adverse events from 17,700 procedures in the United States. Heart Rhythm. 2021;18(9):1508–15. https://doi.org/10.1016/j.hrthm.2021.05.017 .
doi: 10.1016/j.hrthm.2021.05.017 pubmed: 34020049 pmcid: 8558825
Newell P, Zogg C, Shirley H, et al. The effect of psychosocial risk factors on outcomes after aortic valve replacement. JACC Cardiovasc Interv. 2022;15(22):2326–35.
doi: 10.1016/j.jcin.2022.08.014 pubmed: 36423976
DeFilippis EM, Breathett K, Donald EM, et al. Psychosocial risk and its association with outcomes in continuous-flow left ventricular assist device patients. Circ Heart Fail. 2020;13(9):e006910. https://doi.org/10.1016/j.jcin.2022.08.014 .
doi: 10.1016/j.jcin.2022.08.014 pubmed: 32894983 pmcid: 7527209
Nielsen S, Giang KW, Wallinder A, et al. Social factors, sex, and mortality risk after coronary artery bypass grafting: a Population‐Based cohort study. J Am Heart Assoc. 2019;8(6):e011490. https://doi.org/10.1161/JAHA.118.011490 .
doi: 10.1161/JAHA.118.011490 pubmed: 30852925 pmcid: 6475039
Stirbu I, Looman C, Nijhof GJ, Reulings PG, Mackenbach JP. Income inequalities in case death of ischaemic heart disease in the Netherlands: a national record-linked study. J Epidemiol Community Health. 2012;66(12):1159–66. https://doi.org/10.1136/jech-2011-200924 .
doi: 10.1136/jech-2011-200924 pubmed: 22685304
Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873–98. https://doi.org/10.1161/CIR.0000000000000228 .
doi: 10.1161/CIR.0000000000000228 pubmed: 26240271
Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802–13. https://doi.org/10.1097/01.psy.0000146332.53619.b2 .
doi: 10.1097/01.psy.0000146332.53619.b2 pubmed: 15564343
van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Longitudinal relationship of depressive and anxiety symptoms with dyslipidemia and abdominal obesity. Psychosom Med. 2013;75(1):83–9. https://doi.org/10.1097/PSY.0b013e318274d30f .
doi: 10.1097/PSY.0b013e318274d30f pubmed: 23197842
Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord. 2004;79(1-3):81–95. https://doi.org/10.1016/S0165-0327(02)00349-X .
doi: 10.1016/S0165-0327(02)00349-X pubmed: 15023483
Darden D, Duong T, Du C, et al. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry [published correction appears in JAMA Cardiol. 2021 Oct 20;]. JAMA Cardiol. 2021;6(11):1275–84. https://doi.org/10.1001/jamacardio.2021.3021 .
doi: 10.1001/jamacardio.2021.3021 pubmed: 34379072
Bjørnnes AK, Parry M, Lie I, Falk R, Leegaard M, Rustøen T. The association between hope, marital status, depression and persistent pain in men and women following cardiac surgery. BMC Womens Health. 2018;18(1):2. https://doi.org/10.1186/s12905-017-0501-0 .
doi: 10.1186/s12905-017-0501-0 pubmed: 29291728 pmcid: 5749023
Bunker SJ, Colquhoun DM, Esler MD, et al. "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust. 2003;178(6):272–6. https://doi.org/10.5694/j.1326-5377.2003.tb05193.x .
doi: 10.5694/j.1326-5377.2003.tb05193.x pubmed: 12633484
Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
doi: 10.1186/1471-2288-11-83 pubmed: 21619668 pmcid: 3125388
Henderson T, Shepheard J, Sundararajan V. Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care. 2006;44(11):1011–9.
doi: 10.1097/01.mlr.0000228018.48783.34 pubmed: 17063133
Alhajji M, Kawsara A, Alkhouli M. Validation of acute ischemic stroke codes using the international classification of diseases tenth revision. Am J Cardiol. 2020;125(7):1135.
doi: 10.1016/j.amjcard.2020.01.004 pubmed: 31955830
Hirji S, Zogg CK, Kaneko T. The utility of the nationwide readmissions database in understanding contemporary transcatheter aortic valve replacement outcomes. Eur Heart J. 2020;41(45):4358–9. https://doi.org/10.1093/eurheartj/ehaa581 .
doi: 10.1093/eurheartj/ehaa581 pubmed: 32678898
Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev. 2009;14(1):21–8. https://doi.org/10.1007/s10741-007-9075-5 .
doi: 10.1007/s10741-007-9075-5 pubmed: 18214674

Auteurs

Siddharth Agarwal (S)

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Muhammad Bilal Munir (MB)

Division of Cardiovascular Medicine, University of California Davis, Sacramento, CA, USA.

Muhammad Zia Khan (MZ)

Department of Cardiovascular Medicine, West Virginia University Heart & Vascular Institute, Morgantown, WV, USA.

Agam Bansal (A)

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.

Abhishek Deshmukh (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Christopher V DeSimone (CV)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Stavros Stavrakis (S)

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Zain Ul Abideen Asad (ZUA)

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. drzainasad@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH